Veradigm, a healthcare technology company, has concluded its exploration of strategic alternatives without securing a buyer. The company had previously guided revenue expectations for 2023 at $650 million but later revised this figure down to $615 million. Additionally, Veradigm reported an EBITDA of approximately $130 million and net cash of $232 million as of January 2024. The company's recent acquisition, described as a 'literal bag of air' for $140 million, has drawn criticism, with some analysts labeling it one of the worst acquisitions in history. The company's forecast for 2024 EBITDA is now set at $109 million.